Eva Muñoz-Couselo

Eva Muñoz-Couselo

UNVERIFIED PROFILE

Are you Eva Muñoz-Couselo?   Register this Author

Register author
Eva Muñoz-Couselo

Eva Muñoz-Couselo

Publications by authors named "Eva Muñoz-Couselo"

Are you Eva Muñoz-Couselo?   Register this Author

20Publications

451Reads

13Profile Views

The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.

Melanoma Res 2019 Jul 22. Epub 2019 Jul 22.

Medical Oncology Melanoma and Other Skin Tumors Unit, Vall d´Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000632DOI Listing
July 2019

Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?

J Hepatol 2019 Mar 28;70(3):564-566. Epub 2018 Nov 28.

Liver Unit, Internal Medicine Department, Vall d'Hebron Hospital, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2018.10.020DOI Listing
March 2019

DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem.

BMJ Case Rep 2018 Sep 30;2018. Epub 2018 Sep 30.

Medical Oncology, Vall d'Hebrón Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-224379DOI Listing
September 2018

-mutant melanoma: current challenges and future prospect.

Onco Targets Ther 2017 8;10:3941-3947. Epub 2017 Aug 8.

Baselga Institute of Oncology, Hospital Quirón, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S117121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558581PMC
August 2017

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.

Melanoma Res 2015 Dec;25(6):486-95

aTranslational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital bPangaea Biotech S.L cHospital Vall d'Hebron dCatalan Institute of Oncology, Hospital Germans Trias i Pujol Badalona eMORe Foundation, Barcelona fHospital Central Asturias, Oviedo gPivotal SL, Madrid hCUN, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000187DOI Listing
December 2015

The effect of biology in the treatment of small breast tumors.

Am Soc Clin Oncol Educ Book 2013 :25-31

From the Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Medica Scientia Innovation Research (MedSIR), Passeig Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.25DOI Listing
November 2015

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Nat Med 2015 Jul 1;21(7):741-50. Epub 2015 Jun 1.

1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968631PMC
July 2015

Therapeutic antibodies in breast cancer.

Semin Oncol 2014 Oct 21;41(5):576-88. Epub 2014 Jul 21.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.07.002DOI Listing
October 2014

Bone metastases: Causes, consequences and therapeutic opportunities.

EJC Suppl 2013 Sep;11(2):254-6

Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcsup.2013.07.035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041187PMC
September 2013

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.

Onco Targets Ther 2011 14;4:185-92. Epub 2011 Nov 14.

Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S16392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233277PMC
October 2012

The beautiful history of pertuzumab.

Expert Rev Anticancer Ther 2012 Jun;12(6):703-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.46DOI Listing
June 2012

HER2 and hormone receptor-positive breast cancer--blocking the right target.

Nat Rev Clin Oncol 2011 05 14;8(5):307-11. Epub 2010 Dec 14.

Vall d'Hebron University Hospital, Oncology Department, Breast Cancer Unit, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2010.185
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2010.185DOI Listing
May 2011

Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.

Expert Rev Anticancer Ther 2010 Jun;10(6):795-805

Gynecological Cancer Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.10.59DOI Listing
June 2010